|Day Low/High||194.50 / 199.78|
|52 Wk Low/High||187.16 / 468.55|
These four names are soaring, and I'd jump into all of them, even after their recent runs.
Apparently it's 'bad' now that the public has stopped pulling reams of money out of the market.
The market is richly priced right now, but you can still find bargains.
Biogen and Merck earnings emerge as investors wait for the Federal Reserve's latest policy-making statement.
Jim Cramer looks at the top performers of 2013 that should surge into the end of the year, with Mad Money Research Director Nicole Urken.
Use 1684 as your short-term point of reference and keep taking trades in light volume.
These stocks look bound to get bought at every dip through year-end. You should buy up, too -- but wait for that swoon.
Jim Cramer looks at the latest biotech deals as Cubist acquires Trius amid changes among Biotech companies.
Let's take a peek at the price action overnight and in the early morning in the more important asset classes. The rundown: S&P futures down 9 handles; Nikkei down 1.15%; European markets down -- a lot of earnings disappointments overnight, including...
John Darsie of T3Live review the day's market action and sets up your trading plan for the next session.
This sector offers the best growth opportunity over the next decade.
Henry Gambell of Simpler Options steps in for John Carter noting levels we're looking to take profits on SPY and USO along with analysis on GS, BIIB & AWAY.
There have been some really good winners this year. By Bob Lang One of the best sectors to play this year has been the biotechs and I would be remiss if I didn't tell you my best play ever was just a couple weeks ago with Onyx Pharmaceutical (ONXX),...
Brittany Umar and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks ahead of earnings season: retail, banks, tech.